Keros Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
KROS$9.33+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| SEPTEMBER 30,2026 | DECEMBER 31,2025 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $259,464 | $287,415 |
| Accounts receivable | 20,000 | 3,567 |
| Prepaid expenses and other current assets | 5,920 | 22,202 |
| Current income tax receivable | 2,250 | 2,250 |
| Total current assets | 287,634 | 315,434 |
| Operating lease right-of-use assets | 14,887 | 16,841 |
| Property and equipment, net | 3,390 | 4,297 |
| Restricted cash | 1,449 | 1,449 |
| Other long-term assets | 11 | — |
| TOTAL ASSETS | $307,371 | $338,021 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $3,787 | $1,967 |
| Current portion of operating lease liabilities | 2,695 | 2,408 |
| Accrued expenses and other current liabilities | 8,761 | 16,039 |
| Current tax liability | 615 | — |
| Total current liabilities | 15,858 | 20,414 |
| Operating lease liabilities, net of current portion | 12,415 | 14,475 |
| Total liabilities | 28,273 | 34,889 |
| STOCKHOLDERS' EQUITY: | ||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; no shares issued and outstanding | — | — |
| Series A junior participating preferred stock, par value of $0.0001 per share; 500,000 shares authorized as of September 30, 2026 and December 31, 2025; no shares issued and outstanding | — | — |
| Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 41,103,773 shares issued and 19,830,671 shares outstanding as of September 30, 2026 and 40,670,466 shares issued and 19,543,706 shares outstanding as of December 31, 2025 | 4 | 4 |
| Treasury stock, at cost; 21,273,102 shares as of September 30, 2026 and 21,126,760 shares as of December 31, 2025 | (386,211) | (384,558) |
| Additional paid-in capital | 1,185,335 | 1,169,451 |
| Accumulated deficit | (520,030) | (481,765) |
| Total stockholders' equity | 279,098 | 303,132 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $307,371 | $338,021 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.